[Multicentric study on a topical compound with lymph-draining action in the treatment of the phlebostatic ulcer of the inferior limbs]
- PMID: 20109380
[Multicentric study on a topical compound with lymph-draining action in the treatment of the phlebostatic ulcer of the inferior limbs]
Abstract
Phlebostatic sore of the lower limbs is a typical chronic venous insufficiency complication and is still a widely controversial issue in its treatment. The common therapies, in fact, are not yet standardized and they not show complete efficacy. Since 2005 to 2007 a multicentric clinical trial was conducted at the Plastic and Reconstructive Surgery of "Sapienza" University of Rome and at the Plastic and Reconstructive Surgery Department, University of Perugia, in order to evaluate the efficacy of the Idrastin lymph-draining cream in patients with phlebostatic sores of the lower limbs. This study enrolled on 80 patients, split into 2 homogeneous groups of 40 patients: group A was treated by only elastocompressive therapy, group B by elastocompressive therapy and Idrastin. Multicentric analysis has considered the following parameters: local pain, perilesional flogosis , granulation tissue, perilesional tissue tropism healing time. In the group B results highlighted: reduction of the local pain, stopped in 72 hours; flogosis decrease disappeared in one week; tissue granulation growth in one week; lesion healing in 4 weeks. These results pointed out statistically significance of the variables considered. In our opinion Idrastin compounds such as phytoessence of hops and Hedera helix, had contributed to analgesia; Aesculus hippocastanum, and Vitis vinifera and Ruscus aculeatus phytoessence showed anti-flogistic action; allantoin and Centella asiatica and jaluronic acid aided to sore healing. Idrastin gives an effective support to the treatment of the phlebostatic sores warrants a faster and more effective healing process, than to the wounds treated by only the elastocompressive therapy.
Similar articles
-
LINFAVENIX: improvement of signs and symptoms of chronic venous insufficiency and microangiopathy.Minerva Cardioangiol. 2008 Oct;56(5 Suppl):55-61. Minerva Cardioangiol. 2008. PMID: 19597413
-
Initial rate of healing predicts complete healing of venous ulcers.Arch Dermatol. 1997 Oct;133(10):1231-4. Arch Dermatol. 1997. PMID: 9382561
-
Evaluation of healing and antimicrobiological effects of herbal therapy on venous leg ulcer: pilot study.Phytother Res. 2010 Feb;24(2):277-82. doi: 10.1002/ptr.2931. Phytother Res. 2010. PMID: 19610037 Clinical Trial.
-
The ESCHAR trial: should it change practice?Perspect Vasc Surg Endovasc Ther. 2009 Jun;21(2):69-72. doi: 10.1177/1531003509337156. Epub 2009 Jul 14. Perspect Vasc Surg Endovasc Ther. 2009. PMID: 19602507 Review.
-
Clinical inquiry. What is the most effective way to treat recurrent canker sores?J Fam Pract. 2011 Oct;60(10):621-32. J Fam Pract. 2011. PMID: 21977491 Review.
Cited by
-
Dressings and topical agents for treating venous leg ulcers.Cochrane Database Syst Rev. 2018 Jun 15;6(6):CD012583. doi: 10.1002/14651858.CD012583.pub2. Cochrane Database Syst Rev. 2018. PMID: 29906322 Free PMC article.
-
Phlebotonics for venous insufficiency.Cochrane Database Syst Rev. 2016 Apr 6;4(4):CD003229. doi: 10.1002/14651858.CD003229.pub3. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2020 Nov 3;11:CD003229. doi: 10.1002/14651858.CD003229.pub4. PMID: 27048768 Free PMC article. Updated.
-
Phlebotonics for venous insufficiency.Cochrane Database Syst Rev. 2020 Nov 3;11(11):CD003229. doi: 10.1002/14651858.CD003229.pub4. Cochrane Database Syst Rev. 2020. PMID: 33141449 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical